PDS Biotechnology Files Proxy Statement for June 11 Meeting
Ticker: PDSB · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
PDS Biotech proxy filed - vote on directors & auditors for June 11 meeting.
AI Summary
PDS Biotechnology Corporation filed its definitive proxy statement on April 29, 2025, for its annual meeting of stockholders scheduled for June 11, 2025. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company was formerly known as Edge Therapeutics, Inc. and was incorporated in Delaware.
Why It Matters
This filing is crucial for shareholders as it details the agenda for the annual meeting, allowing them to make informed decisions on corporate governance and the company's future direction.
Risk Assessment
Risk Level: medium — Proxy statements are routine filings, but the specific proposals and the company's financial health can introduce medium-level risk for investors.
Key Numbers
- 001-37568 — SEC File Number (Identifies the company's filings with the SEC.)
- 25887147 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- June 11, 2025 (date) — Annual Meeting Date
- April 29, 2025 (date) — Filing Date
- Edge Therapeutics, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the annual meeting of stockholders, including proposals to be voted upon, such as the election of directors and ratification of the independent auditor.
When is the PDS Biotechnology Corporation's annual meeting of stockholders scheduled?
The annual meeting of stockholders is scheduled for June 11, 2025.
Who is the filer of this proxy statement?
The filer is PDS Biotechnology Corporation, the Registrant.
What was PDS Biotechnology Corporation's former name?
PDS Biotechnology Corporation was formerly known as Edge Therapeutics, Inc.
On what date was this definitive proxy statement filed with the SEC?
This definitive proxy statement was filed with the SEC on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding PDS Biotechnology Corp (PDSB).